Molecular characteristics and clinical implications of TP53 mutations in therapy-related myelodysplastic syndromes

Le résumé fourni par la source

TP53 mutations ( TP53 mut ) are observed in approximately 10% of patients with myelodysplastic syndromes (MDS) and associated with a high risk of acute myeloid leukemia (AML) transformation, poor response to conventional therapies, and dismal outcomes [ 1 , 2 , 3 , 4 ]. Recent updates by the World Health Organization (WHO) and International Consensus Classification (ICC) have incorporated TP53 mut into the classification of MDS [ 5 , 6 ]. Despite critical differences in the definition of TP53 allelic status, both classifications strongly emphasized the poor prognostic impact of multi-hit TP53 mut . However, these changes were driven by data predominantly came from primary MDS (p-MDS) [ 1 , 2 , 3 ], while studies focusing specifically on TP53 mut in therapy-related MDS (t-MDS) remain limited [ 7 , 8 , 9 ]. Here, we conducted a comprehensive analysis of the molecular characteristics and clinical implications of TP53 mut in the context of t-MDS and compared them with those of p-MDS.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.